Novartis: Hidradenitis Suppurativa trials
The registry lists 21 Hidradenitis Suppurativa studies with Novartis as lead sponsor. 10 are open to participants now and 5 have results posted.
Phase 1 1Phase 2 2Phase 3 6Phase 4 1No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruitingNCT07855276Phase 1
- A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa PatientsNot yet recruitingNCT07690319
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruitingNCT07665437Phase 3
- Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian PopulationRecruitingNCT07543419
- Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07489573Phase 4
- A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With SecukinumabNot yet recruitingNCT07454889
- Real-world Secukinumab Outcomes in Canadian HS PatientsRecruitingNCT07282015
- Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in KoreaRecruitingNCT07243782
- Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi ArabiaRecruitingNCT06785779
- Managed Access Programs for AIN457, SecukinumabAvailableNCT05583604
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis SuppurativaCompletedNCT04179175Phase 3Results posted
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03827798Phase 2Results posted
- Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT03713632Phase 3Results posted
- This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).CompletedNCT03713619Phase 3Results posted
- Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa PatientsCompletedNCT02421172Phase 2Results posted
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06840392Phase 3
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active, not recruitingNCT06799000Phase 3
- Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.CompletedNCT06785675
- Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian FederationActive, not recruitingNCT06517732
- Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab InitiationActive, not recruitingNCT06444087
- Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.Active, not recruitingNCT05921994